Establishment Labs (ESTA) Set to Announce Quarterly Earnings on Thursday

Establishment Labs (NASDAQ:ESTA) will likely be posting its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.2568) per share and revenue of $66.81 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Establishment Labs (NASDAQ:ESTA) last issued its earnings results on Thursday, August 6th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). The company had revenue of $67.54 million during the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%. Establishment Labs’s quarterly revenue was up 31.7% on a year-over-year basis. During the same period in the prior year, the business earned ($0.57) earnings per share. On average, analysts expect Establishment Labs to post ($1.08) EPS for the current fiscal year and ($0.01) EPS for the next fiscal year.

Establishment Labs Stock Performance

ESTA stock opened at $62.28 on Thursday. The company has a debt-to-equity ratio of 12.11, a quick ratio of 2.52 and a current ratio of 3.84. The stock has a market capitalization of $1.86 billion, a price-to-earnings ratio of -47.54 and a beta of 1.06. Establishment Labs has a 1 year low of $47.00 and a 1 year high of $97.59. The stock’s fifty day moving average is $68.43 and its two-hundred day moving average is $74.56.

Analysts Set New Price Targets

Several equities analysts have recently commented on ESTA shares. Mizuho upped their price target on shares of Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 15th. TD Cowen reiterated a “buy” rating and issued a $117.00 price objective on shares of Establishment Labs in a research report on Thursday, October 15th. JPMorgan Chase & Co. lifted their price objective on shares of Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Canaccord Genuity Group set a $105.00 target price on shares of Establishment Labs in a research note on Thursday, August 6th. Finally, Stifel Nicolaus set a $85.00 target price on shares of Establishment Labs and gave the company a “buy” rating in a research note on Wednesday, October 14th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $98.56.

About Establishment Labs

Establishment Labs Holdings Inc is a medical technology company focused on women’s health and the breast aesthetics market. The company develops, manufactures and commercializes breast implants and related technologies designed for breast augmentation, reconstruction and revision procedures.

Its product portfolio includes the Motiva line of breast implants, which incorporates the company’s proprietary implant materials, surface technologies and design features. Establishment Labs also offers Motiva Flora tissue expanders for use in breast reconstruction and has developed Mia Femtech, a minimally invasive breast enhancement procedure intended to provide a less invasive alternative to traditional augmentation techniques.

Founded in 2004, Establishment Labs is headquartered in Costa Rica and serves physicians, hospitals and patients in international markets.